Interleukin 10 and arthritis
It is now almost 10 yr since interleukin 10 (IL-10) was
Investigations into the role of IL-10 in arthritis started first described as a murine Th2 cell product, which in the early 1990s. The presence of IL-10 was found in inhibited cytokine synthesis [especially interferon gamma RA peripheral blood [18] synovial joints by reverse (IFN-c)] by Th1 cells [1] . Studies since then have transcriptase-polymerase chain reaction ( RT-PCR), indicated that it also inhibits many aspects of immune immunostaining, and by assay of 24 h culture supernatfunction, and that its synthesis is not restricted to Th2
ants of dissociated joint cell cultures [19, 20] . It was cells as it is also produced by CD4+ Th0 and Th1 cells, also found that the endogenous IL-10 in these RA CD8+ T cells, B cells, keratinocytes, various tumour synovial cell cultures was functional, since inhibition of cell lines and in particular monocytes/macrophages its activity using a neutralizing monoclonal antibody (reviewed) [2] . Based on its potent immunoregulatory enhanced TNF-a and IL-1 production, and that addition activities, attention has not unsurprisingly focused upon of recombinant IL-10 inhibited TNF-a and IL-1 producthe potential therapeutic use of this cytokine to treat tion by~50% in cultures [19] . In a similar study, but chronic inflammatory diseases such as rheumatoid arthusing synovial tissue organ cultures [15] , it was observed ritis (RA). In this short editorial, I will discuss those that exogenous IL-10 also inhibited IL-1b, although studies which have investigated IL-10 in arthritis, prelim-IL-4 was more potent, and additionally that IL-4 (but inary results from clinical trials using IL-10, and recent not IL-10) induced the production of the native inhibitor studies investigating whether IL-10 polymorphisms are of IL-1, IL-1ra. In addition, IL-10 seems to ameliorate associated with arthritic disease.
the degradation of cartilage and bone by inhibiting the IL-10 functions as an effective immunoregulatory synthesis of matrix metalloproteinases (MMPs) such as molecule based on two important functions: inhibition collagenase in stimulated human monocytes, and by of cytokine synthesis and downregulation of antigenincreasing the synthesis of the natural MMP inhibitor presenting cell function [3] [4] [5] . This latter activity is TIMP-1 (tissue inhibitor of metalloproteinase) [21] . largely due to the ability of IL-10 to downregulate both These observations on human RA tissue, and the constitutive and induced expression of HLA-DR, finding that collagen-induced arthritic (CIA) mice HLA-DP and HLA-DQ [6 ], and co-stimulatory molreceiving neutralizing anti-IL-10 antibodies developed ecules such as B7-1 and 2 [5, [7] [8] [9] . accelerated more severe disease [22] , prompted theraIt is generally thought that the inhibitory effect of peutic studies in animals with established disease. Studies IL-10 upon T cells is indirect via its ability to inhibit in our group demonstrated that recombinant murine cytokine synthesis from monocytes [7] . The range of IL-10 was therapeutically active in collagen type macrophage-derived cytokines which IL-10 inhibits is II-induced arthritis in mice when delivered by a single truly impressive and includes IL-1, IL-6, IL-12, IFN-a, daily i.p. injection and significantly inhibited clinical tumour necrosis factor alpha ( TNF-a), granulocytedisease progression at a dose of 5 mg/day [23]. macrophage, colony stimulating factor (GM-CSF ) and Additional studies have also demonstrated the theragranulocyte colony stimulating factor (G-CSF ), but also peutic potential of IL-10 in vivo. A pre-clinical 48 day chemokines such as IL-8 and macrophage inflammatory course of IL-10 treatment at a dose of 100 ng/day was protein (MIP)-1a [4, 10] at both protein and mRNA found to suppress significantly the clinical severity of levels. The mechanism by which IL-10 inhibits cytokine collagen-induced arthritis in DBA/1 mice [24] . synthesis is somewhat contradictory. Some studies have Importantly, no augmentation of the anti-collagen antiindicated that IL-10 inhibits TNF synthesis through body response was observed in treated mice. In another blockade of gene transcription [11] , mediated possibly study, treatment of established collagen-induced arthritis via effects on NF-kB [12] . Other reports suggest the with recombinant IL-10 mildly suppressed clinical diseffect of IL-10 to be mainly post-transcriptional [13] . It ease; however, the clinical benefit was markedly augis likely, however, that all of these observations are mented by combination treatment with IL-4 [25] . This correct, and that IL-10's inhibitory effects are at multiple combination of IL-10 and IL-4 was also effective in levels. This is reflected in the observation that IL-10 will streptococcal cell wall arthritis [26 ] , and in both models inhibit TNF production in either resting or pre-activated accelerated onset of disease was observed following cells [14] . IL-10 can also induce the production of treatment with neutralizing anti-IL-10 antibodies, sugcytokine inhibitors. These include the IL-1 receptor gesting a dominant role for IL-10 in the natural suppresantagonist (IL-1ra) [15] and the release of both soluble sion of arthritis in this model system. More recently, TNF receptors: p55 and p75 in monocytes and in RA suppression of arthritis in CIA has been achieved using mononuclear membrane culture [16 ] . These results coladenoviral vectors to deliver viral IL-10 to the mice [27, lectively indicate that IL-10 exerts strong anti-28]. Viral IL-10 has the advantage (and possibly disadinflammatory activities and thus has been termed a 'macrophage deactivating factor' [17] .
vantage) of not binding to T lymphocytes (presumably due to receptor expression) and thus will not exhibit the the thrombocytopenia observed in the clinical trial at the higher dose of IL-10 was totally unpredicted. Trials full spectrum of biological functions as human/mouse IL-10.
are currently under way focusing on IL-10 dosage within the area of efficacy, and plans are being made for Since IL-10 is effective in animal models of arthritis, there clearly has been interest to establish whether IL-10 combination trials with methotrexate. Of interest in this regard are recent studies from our group investigating is also effective in human RA. The safety issues regarding IL-10 have been examined, and IL-10 administered to the role of IL-11 in RA [32] . IL-11 is a member of the IL-6 supergene family which was reported to inhibit healthy volunteers in a single i.v. bolus injection demonstrated no clinical adverse event [29] . In vitro studies on lipopolysaccharide (LPS)-stimulated TNF production in mouse macrophages [33] . We found abundant IL-11 isolated peripheral blood mononuclear cells from those IL-10-treated volunteers showed a transient reduction in RA synovial joint cell cultures, and blocking its activity resulted in a modest, but significant, 2-fold in phytohaemagglutinin-stimulated T-cell proliferation and a marked inhibition of endotoxin-induced IL-1b and increase in TNF production. What was unexpected, however, was the effect of neutralizing both endogenous TNF-a production, whereas their respective antagonists remained unaffected.
IL-10 and IL-11; this resulted in a 22-fold increase in TNF levels. This suggests that the regulation of proIn light of this background, a recent trial of recombinant human IL-10 in subjects with active RA was perinflammatory cytokines is highly complex, and that interactions and synergies between different molecules formed [30] . The primary objective of this trial was to assess the safety and tolerability of rIL-10 and, secondarare a key component in this process. Combining IL-10 and IL-11 in a clinical trial is not necessarily the answer, ily, to evaluate its effect on disease activity and on cytokine physiology. In this multicentre, randomized, but undoubtedly future therapeutics will wish to capitalize on the maximum benefits a drug gives, with the double-blind, placebo-controlled, multiple-dose study, after a 4 week wash-out period of disease-modifying minimum side-effects achieved using sub-optimal amounts of two different therapeutics. anti-rheumatic drugs (DMARDs), 72 subjects with active RA received rIL-10 at doses of 0.5, 1.0, 5, 10, In common with other cytokines which have been associated with arthritic disease, the IL-10 gene has been 20 mg/kg or placebo by daily s.c. injections for 4 weeks. rIL-10 was clinically well tolerated and no anti-IL-10 subject to polymorphic analysis. The IL-10 gene is highly polymorphic with two microsatellites (dinucleotide antibodies were detected in any subjects at any time during the study. During treatment, there was a reducrepeats) at 1.4 kB (IL-10.G) and 4.1 kB (IL-10.R). In addition, there are three single-nucleotide repeats at tion in mean platelets in subjects treated with the highest rIL-10 doses, although overall rIL-10 was well tolerated −1082, −819 and −592. Differences in IL-10 secretion have been assigned to the −1082 polymorphism [34] and safe. Despite the beneficial effects of IL-10 in murine CIA, the clinical effects of IL-10 in this trial of human and a more recent study [35] indicated that IL-10 secretion from LPS-stimulated whole blood cultures RA were marginal with a beneficial trend towards improvement in RA disease activity at 4 weeks (>20% varied according to the IL-10 locus, as assigned by allelic haplotypes at the 4.1 kB microsatellite. The ACR criteria) only observed in the 5 mg/kg rIL-10 group. However, subjects receiving doses of rIL-10 obvious question thus emerges: are certain IL-10 polymorphisms associated with disease? Two separate required less use of DMARDs during the 8 weeks following completion of therapy. Circulating levels of reports indicated that there was no difference in allele or haplotype frequency between controls and RA soluble TNF-R (p55 and p75) as well as IL-1ra showed a significant increase (P < 0.001 for the former and patients with respect to the −1082, −819 and −592 polymorphisms [36, 37] , whereas a recent report com-P < 0.01 for the latter) at the highest rIL-10 doses, indicating that the IL-10 was having a biological role paring the microsatellite alleles in RA and controls indicated that the IL-10.R2 microsatellite allele was in vivo.
Two important issues have arisen from this trial. The overrepresented in RA. Interestingly, this allele is associated with increased IL-10 synthesis, suggesting that first is that despite good indications from animal studies, pre-clinical trials may not always translate well to the rather than IL-10 being protective, it may have proinflammatory properties such as RF induction titres [20, clinic. Secondly, whilst IL-10 has many immunoregulatory functions, it also has activities which could be 31]. However, as genetic studies are complex, and published reports do not always agree, this observation [38] considered as immunostimulatory. For example, circulating B cells require IL-10 to reach terminal maturation needs to be confirmed before firm conclusions can be made. in order to produce IgM-rheumatoid factor (IgM-RF ), and in RA serum, IL-10 levels correlate with IgM-RF
In conclusion, IL-10 is a very potent immunoregulatory cytokine, which, despite encouraging results in titres [20, 31] , indicating that IL-10 may stimulate humoral immune responses, worsening disease activity therapeutic trials in animal models, still needs to 'deliver' in the clinic. The lack of good 'clear-cut' results in correlated with high RF production. Interestingly, whilst IL-10 treatment in DA rats with established disease clinical trials is not restricted to RA, as phase I trials in Crohn's disease have had limited success [39] . It remains reduced paw swelling, higher levels of autoantibody production to collagen type II were observed. However, to be seen whether in the future IL-10, either alone or 
Prolactin, the immune response and lupus
The interactions between endocrinology and immunosome women with hyperprolactinaemia have demonstrated a number of circulating autoantibodies, including logy have recently been further highlighted by the publication of a special edition of the journal Lupus devoted antibodies to DNA, anticardiolipin antibodies and antiendothelial antibodies. to prolactin in systemic lupus erythematosus (SLE ) [1] .
This issue, edited by Sara Walker and Luis Jara, two A number of studies have now reported the presence of hyperprolactinaemia in lupus and the summary of major students of this subject, brings together a number of papers linking hyperprolactinaemia with alterations these reports is analysed in the editorial by Walker and colleagues introducing the Lupus supplement. in the immune response and with clinical fluctuations in human and murine lupus.
These observations raise interesting questions regarding the relative roles of the hormones prolactin and Such is the strength of the association between hyperprolactinaemia and lupus activity noted in some studies, oestrogen in SLE. Certainly, in animal experiments, notably in the New Zealand lupus mouse model, the that therapeutic trials of bromocriptine in lupus are already appearing. production of hyperprolactinaemia has been shown to accelerate the production of antibodies to DNA, to To date, the majority of reports of hyperprolactinaemia in lupus are anecdotal. Nevertheless, their number result in hypergammaglobulinaemia, and to produce earlier renal disease and premature mortality. is increasing and at the recent 5th International Conference on SLE, no less than 17 studies relating to Conversely, the giving of daily injections of bromocriptine to produce hypoprolactinaemia delayed the appearthe association were presented [2] .
Prolactin, a functional cytokine, is secreted by a ance of anti-DNA antibodies and prolonged survival. suggested that a normal level of serum prolactin is necessary for oestrogen to act as a stimulant in the Interferon regulatory factor-1 (IRF ), an important regulator of T-and B-cell differentiation, has been murine model of SLE. Clinical studies demonstrated hyperprolactinaemia in shown to be sensitive to stimulation by prolactin.
Prolactin is also a stimulator of macrophages, increas-28% of SLE patients (Jimena et al.) and a possible association with renal disease (Miranda et al.) . In a trial ing (in mice) production of macrophage interleukin-1 and nitric oxide, and stimulating phagocytic activity.
of bromocriptine (2.5 mg daily) in 66 lupus patients from Jara's group in Mexico, significant improvement Conversely, hypoprolactinaemia has been shown to be associated with macrophage depletion.
in the lupus activity index was found in the treated group compared with controls (Alvarez-Nemegyei A number of patients with autoimmune diseases have been reported with hyperprolactinaemia and sera from et al.).
It is well known that hyperprolactinaemia is a Lupus Research Unit, Rayne Institute, St Thomas' common finding, associated with stress, pregnancy, Hospital, London SE1, UK breast feeding, renal failure and a variety of medications. Those taking part in these studies were well aware of
